Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Breast Neoplasms 2Vomiting 1Triple Negative Breast Neoplasms 1Postoperative Nausea and Vomiting 1Neoplasm Metastasis 1Carcinoma 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Famotidine × Breast × Clear all
NCT02473042 2025-12-05

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

M.D. Anderson Cancer Center

Phase NA Completed
188 enrolled 11 charts
Breast

Breast Neoplasms, Vomiting, Postoperative Nausea and Vomiting

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡